{"parse":{"title":"Cancer vaccine","pageid":793631,"revid":859689143,"text":{"*":"<div class=\"mw-parser-output\"><div role=\"note\" class=\"hatnote navigation-not-searchable\">This article is about therapeutic cancer vaccines. For preventive cancer vaccine, see <a href=\"/wiki/Cancer_immunoprevention\" title=\"Cancer immunoprevention\">cancer immunoprevention</a>.</div>\n<p>A <b>cancer vaccine</b> is a <a href=\"/wiki/Vaccine\" title=\"Vaccine\">vaccine</a> that either treats existing <a href=\"/wiki/Cancer\" title=\"Cancer\">cancer</a> or prevents development of a cancer. Vaccines that treat existing cancer are known as <i>therapeutic</i> cancer vaccines.\n</p><p>Some/many of the vaccines are \"autologous\", being prepared from samples taken from the patient, and are specific to that patient.\n</p><p>Some researchers claim that cancerous cells routinely arise and are destroyed by the immune system;<sup id=\"cite_ref-1\" class=\"reference\"><a href=\"#cite_note-1\">&#91;1&#93;</a></sup> and that tumors form when the immune system fails to destroy them.<sup id=\"cite_ref-2\" class=\"reference\"><a href=\"#cite_note-2\">&#91;2&#93;</a></sup>\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Traditional_vaccines\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Traditional vaccines</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Method\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Method</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#Clinical_trials\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Clinical trials</span></a></li>\n<li class=\"toclevel-1 tocsection-4\"><a href=\"#Approved_oncovaccines\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Approved oncovaccines</span></a></li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#Abandoned_research\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">Abandoned research</span></a></li>\n<li class=\"toclevel-1 tocsection-6\"><a href=\"#Desirable_characteristics\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">Desirable characteristics</span></a></li>\n<li class=\"toclevel-1 tocsection-7\"><a href=\"#Antigen_candidates\"><span class=\"tocnumber\">7</span> <span class=\"toctext\">Antigen candidates</span></a></li>\n<li class=\"toclevel-1 tocsection-8\"><a href=\"#Hypothesized_problems\"><span class=\"tocnumber\">8</span> <span class=\"toctext\">Hypothesized problems</span></a></li>\n<li class=\"toclevel-1 tocsection-9\"><a href=\"#Recommendations\"><span class=\"tocnumber\">9</span> <span class=\"toctext\">Recommendations</span></a></li>\n<li class=\"toclevel-1 tocsection-10\"><a href=\"#See_also\"><span class=\"tocnumber\">10</span> <span class=\"toctext\">See also</span></a></li>\n<li class=\"toclevel-1 tocsection-11\"><a href=\"#References\"><span class=\"tocnumber\">11</span> <span class=\"toctext\">References</span></a></li>\n<li class=\"toclevel-1 tocsection-12\"><a href=\"#External_links\"><span class=\"tocnumber\">12</span> <span class=\"toctext\">External links</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Traditional_vaccines\">Traditional vaccines</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Cancer_vaccine&amp;action=edit&amp;section=1\" title=\"Edit section: Traditional vaccines\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Some <a href=\"/wiki/Types_of_cancer\" class=\"mw-redirect\" title=\"Types of cancer\">types of cancer</a>, such as <a href=\"/wiki/Cervical_cancer\" title=\"Cervical cancer\">cervical cancer</a> and some <a href=\"/wiki/Hepatocellular_carcinoma\" title=\"Hepatocellular carcinoma\">liver cancers</a>, are caused by viruses (oncoviruses). Traditional vaccines against those viruses, such as <a href=\"/wiki/HPV_vaccine\" title=\"HPV vaccine\">HPV vaccine</a><sup id=\"cite_ref-Babu2010_3-0\" class=\"reference\"><a href=\"#cite_note-Babu2010-3\">&#91;3&#93;</a></sup> and <a href=\"/wiki/Hepatitis_B_vaccine\" title=\"Hepatitis B vaccine\">hepatitis B vaccine</a>, prevent those types of cancer. These vaccines are not further discussed in this article. Other cancers are to some extent caused by bacterial infections (e.g. stomach cancer and <i><a href=\"/wiki/Helicobacter_pylori\" title=\"Helicobacter pylori\">Helicobacter pylori</a></i><sup id=\"cite_ref-4\" class=\"reference\"><a href=\"#cite_note-4\">&#91;4&#93;</a></sup>). Traditional vaccines against cancer-causing bacteria (oncobacteria) are not further discussed in this article.\n</p>\n<h2><span class=\"mw-headline\" id=\"Method\">Method</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Cancer_vaccine&amp;action=edit&amp;section=2\" title=\"Edit section: Method\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>One approach to cancer vaccination is to separate proteins from cancer cells and immunize patients against those proteins as antigens, in the hope of stimulating the immune system to kill the cancer cells. Research on cancer vaccines is underway for treatment of breast, lung, colon, skin, kidney, prostate and other cancers.<sup id=\"cite_ref-5\" class=\"reference\"><a href=\"#cite_note-5\">&#91;5&#93;</a></sup>\n</p><p>Another approach is to generate an immune response <i>in situ</i> in the patient using <a href=\"/wiki/Oncolytic_viruses\" class=\"mw-redirect\" title=\"Oncolytic viruses\">oncolytic viruses</a>. This approach was used in the drug <a href=\"/wiki/Talimogene_laherparepvec\" title=\"Talimogene laherparepvec\">talimogene laherparepvec</a>, a version of <a href=\"/wiki/Herpes_simplex_virus\" title=\"Herpes simplex virus\">herpes simplex virus</a> engineered to selectively replicate in tumor tissue and to express the immune stimulatory protein <a href=\"/wiki/GM-CSF\" class=\"mw-redirect\" title=\"GM-CSF\">GM-CSF</a>. This enhances the anti-tumor immune response to <a href=\"/wiki/Tumor_antigen\" title=\"Tumor antigen\">tumor antigens</a> released following viral lysis and provides a patient-specific vaccine.<sup id=\"cite_ref-:0_6-0\" class=\"reference\"><a href=\"#cite_note-:0-6\">&#91;6&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Clinical_trials\">Clinical trials</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Cancer_vaccine&amp;action=edit&amp;section=3\" title=\"Edit section: Clinical trials\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>In a phase III trial of <a href=\"/wiki/Follicular_lymphoma\" title=\"Follicular lymphoma\">follicular lymphoma</a> (a type of non-Hodgkin's lymphoma), investigators reported that the <a href=\"/wiki/BiovaxID\" class=\"mw-redirect\" title=\"BiovaxID\">BiovaxID</a> (on average) prolonged remission by 44.2 months, versus 30.6 months for the control.<sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup>\n</p><p>On April 14, 2009, <a href=\"/wiki/Dendreon\" title=\"Dendreon\">Dendreon</a> Corporation announced that their Phase III clinical trial of <a href=\"/wiki/Sipuleucel-T\" title=\"Sipuleucel-T\">sipuleucel-T</a>, a cancer vaccine designed to treat prostate cancer, had demonstrated an increase in survival. It received <a href=\"/wiki/Food_and_Drug_Administration_(United_States)\" class=\"mw-redirect\" title=\"Food and Drug Administration (United States)\">U.S. Food and Drug Administration</a> (FDA) approval for use in the treatment of advanced prostate cancer patients on April 29, 2010.<sup id=\"cite_ref-8\" class=\"reference\"><a href=\"#cite_note-8\">&#91;8&#93;</a></sup><sup id=\"cite_ref-9\" class=\"reference\"><a href=\"#cite_note-9\">&#91;9&#93;</a></sup>\n</p><p>On April 8, 2008, New York\u2013based company Antigenics announced that it had received approval for the first therapeutic cancer vaccine in Russia. It is the first approval by a regulatory body of a cancer immunotherapy. The treatment, <a href=\"/wiki/Oncophage\" title=\"Oncophage\">Oncophage</a>, increased recurrence-free survival by a little more than a year according to the results of a phase III clinical trial. The approval is for a subset of <a href=\"/wiki/Kidney_cancer\" title=\"Kidney cancer\">kidney cancer</a> patients who are at intermediate risk for disease recurrence. It awaits approval in the US and EU.<sup id=\"cite_ref-10\" class=\"reference\"><a href=\"#cite_note-10\">&#91;10&#93;</a></sup> but will need a new trial for FDA approval.\n</p><p>Interim results from a phase III trial of <a href=\"/wiki/Talimogene_laherparepvec\" title=\"Talimogene laherparepvec\">talimogene laherparepvec</a> in melanoma showed a significant tumour response compared to administration of GM-CSF alone.<sup id=\"cite_ref-:0_6-1\" class=\"reference\"><a href=\"#cite_note-:0-6\">&#91;6&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Approved_oncovaccines\">Approved oncovaccines</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Cancer_vaccine&amp;action=edit&amp;section=4\" title=\"Edit section: Approved oncovaccines\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p><a href=\"/wiki/Oncophage\" title=\"Oncophage\">Oncophage</a> was approved in Russia in 2008 for <a href=\"/wiki/Kidney_cancer\" title=\"Kidney cancer\">kidney cancer</a>. It is marketed by Antigenics Inc.\n</p><p>Sipuleucel-T, <a href=\"/wiki/Provenge\" class=\"mw-redirect\" title=\"Provenge\">Provenge</a>, was approved by the FDA in April 2010 for metastatic <a href=\"/wiki/Hormone-refractory_prostate_cancer\" class=\"mw-redirect\" title=\"Hormone-refractory prostate cancer\">hormone-refractory prostate cancer</a>. It is marketed by <a href=\"/wiki/Dendreon\" title=\"Dendreon\">Dendreon</a> Corp.\n</p>\n<h2><span class=\"mw-headline\" id=\"Abandoned_research\">Abandoned research</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Cancer_vaccine&amp;action=edit&amp;section=5\" title=\"Edit section: Abandoned research\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p><a href=\"/wiki/CancerVax\" title=\"CancerVax\">CancerVax</a> (Canvaxin), Genitope Corp (MyVax personalized immunotherapy), and FavId (Favrille Inc) are examples of cancer vaccine projects that have been terminated, due to poor phase III results.\n</p>\n<h2><span class=\"mw-headline\" id=\"Desirable_characteristics\">Desirable characteristics</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Cancer_vaccine&amp;action=edit&amp;section=6\" title=\"Edit section: Desirable characteristics\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Cancer vaccines seek to target a tumor-specific <a href=\"/wiki/Antigen\" title=\"Antigen\">antigen</a> and distinct from self-proteins. Selection of the appropriate <a href=\"/wiki/Immunologic_adjuvant\" title=\"Immunologic adjuvant\">adjuvant</a> to activate antigen-presenting cells to stimulate immune responses, is required. <a href=\"/wiki/Bacillus_Calmette-Gu%C3%A9rin\" class=\"mw-redirect\" title=\"Bacillus Calmette-Gu\u00e9rin\">Bacillus Calmette-Gu\u00e9rin</a>, an aluminum-based salt, and a squalene-oil-water emulsion are approved for clinical use. An effective vaccine also should seek to stimulate long term memory to prevent tumor recurrence. Some scientists claim both the <a href=\"/wiki/Innate_immune_system\" title=\"Innate immune system\">innate</a> and <a href=\"/wiki/Adaptive_immune_system\" title=\"Adaptive immune system\">adaptive immune systems</a> must be activated to achieve total tumor elimination.<sup id=\"cite_ref-Pejawar-Gaddy_S_2008_11-0\" class=\"reference\"><a href=\"#cite_note-Pejawar-Gaddy_S_2008-11\">&#91;11&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Antigen_candidates\">Antigen candidates</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Cancer_vaccine&amp;action=edit&amp;section=7\" title=\"Edit section: Antigen candidates\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p><a href=\"/wiki/Tumor_antigen\" title=\"Tumor antigen\">Tumor antigens</a> have been divided into two categories: <i>shared</i> tumor antigens; and <i>unique</i> tumor antigens. Shared antigens are expressed by many tumors. Unique tumor antigens result from mutations induced through physical or chemical carcinogens; they are therefore expressed only by individual tumors.\n</p><p>In one approach, vaccines contain whole tumor cells, though these vaccines have been less effective in eliciting immune responses in spontaneous cancer models. Defined tumor antigens decrease the risk of autoimmunity, but because the immune response is directed to a single <a href=\"/wiki/Epitope\" title=\"Epitope\">epitope</a>, tumors can evade destruction through antigen loss variance. A process called \"epitope spreading\" or \"provoked immunity\" may mitigate this weakness, as sometimes an immune response to a single antigen can lead to immunity against other antigens on the same tumor.<sup id=\"cite_ref-Pejawar-Gaddy_S_2008_11-1\" class=\"reference\"><a href=\"#cite_note-Pejawar-Gaddy_S_2008-11\">&#91;11&#93;</a></sup>\n</p><p>For example, since Hsp70 plays an important role in the presentation of antigens of destroyed cells including cancer cells,<sup id=\"cite_ref-12\" class=\"reference\"><a href=\"#cite_note-12\">&#91;12&#93;</a></sup> this protein may be used as an effective adjuvant in the development of antitumor vaccines.<sup id=\"cite_ref-13\" class=\"reference\"><a href=\"#cite_note-13\">&#91;13&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Hypothesized_problems\">Hypothesized problems</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Cancer_vaccine&amp;action=edit&amp;section=8\" title=\"Edit section: Hypothesized problems\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>A vaccine against a particular virus is relatively easy to create. The virus is foreign to the body, and therefore expresses <a href=\"/wiki/Antigen\" title=\"Antigen\">antigens</a> that the <a href=\"/wiki/Immune_system\" title=\"Immune system\">immune system</a> can recognize. Furthermore, viruses usually only provide a few viable variants. By contrast, developing vaccines for viruses that mutate constantly such as <a href=\"/wiki/Influenza\" title=\"Influenza\">influenza</a> or <a href=\"/wiki/HIV\" title=\"HIV\">HIV</a> has been problematic.\n</p><p>A tumour can have many cell types of cells, each with different cell-surface antigens. Those cells are derived from each patient and display few if any antigens that are foreign to that individual. This makes it difficult for the immune system to distinguish cancer cells from normal cells. Some scientists believe that <a href=\"/wiki/Renal_cancer\" class=\"mw-redirect\" title=\"Renal cancer\">renal cancer</a> and <a href=\"/wiki/Melanoma\" title=\"Melanoma\">melanoma</a> are the two cancers with most evidence of spontaneous and effective immune responses, possibly because they often display antigens that are evaluated as foreign. Many attempts at developing cancer vaccines are directed against these tumors. However, Provenge's success in prostate cancer, a disease that never spontaneously regresses, suggests that cancers other than melanoma and renal cancer may be equally amenable to immune attack.\n</p><p>However, most vaccine clinical trials have failed or had modest according to the standard <a href=\"/wiki/RECIST\" class=\"mw-redirect\" title=\"RECIST\">RECIST</a> criteria.<sup id=\"cite_ref-14\" class=\"reference\"><a href=\"#cite_note-14\">&#91;14&#93;</a></sup> The precise reasons are unknown, but possible explanations include:\n</p>\n<ul><li>Disease stage too advanced: bulky tumor deposits actively suppress the immune system using mechanisms such as secretion of <a href=\"/wiki/Cytokines\" class=\"mw-redirect\" title=\"Cytokines\">cytokines</a> that inhibit immune activity. The most suitable stage for a cancer vaccine is likely to be early, when the tumor volume is low, which complicates the trial process, which take upwards of five years and require many patients to reach measurable end points. One alternative is to target patients with residual disease after surgery, radiotherapy or chemotherapy that does not harm the immune system.</li>\n<li>Escape loss variants (that target a single <a href=\"/wiki/Tumor_antigen\" title=\"Tumor antigen\">tumor antigen</a>) are likely to be less effective. Tumors are heterogeneous and antigen expression differs markedly between tumors (even in the same patient). The most effective vaccine is likely to raise an immune response against a broad range of tumor antigens to minimise the chance of the tumor mutating and becoming resistant to the therapy.</li>\n<li>Prior treatments may have modified tumors in ways that nullify the vaccine. (Numerous clinical trials treated patients following chemotherapy that may destroy the immune system. Patients who are immune suppressed are not good candidates for vaccines.)</li>\n<li>Some tumors progress rapidly and/or unpredictably, and they can outpace the immune system. Developing a mature immune response to a vaccine may require months, but some cancers (e.g. advanced pancreatic) can kill patients in less time.</li>\n<li>Many cancer vaccine clinical trials target patients' immune responses. Correlations typically show that the patients with the strongest immune responses lived the longest, offering evidence that the vaccine is working. An alternative explanation is that patients with the best immune responses were healthier patients with a better prognosis, and would have survived longest even without the vaccine.</li></ul>\n<h2><span class=\"mw-headline\" id=\"Recommendations\">Recommendations</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Cancer_vaccine&amp;action=edit&amp;section=9\" title=\"Edit section: Recommendations\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>In January 2009, a review article made recommendations for success as follows:<sup id=\"cite_ref-15\" class=\"reference\"><a href=\"#cite_note-15\">&#91;15&#93;</a></sup>\n</p>\n<ul><li>Target settings with a low disease burden.</li>\n<li>Conduct randomized Phase II trials so that the Phase III program is sufficiently <a href=\"/wiki/Statistical_power\" class=\"mw-redirect\" title=\"Statistical power\">powered</a>.</li>\n<li>Do not randomize antigen plus adjuvant versus adjuvant alone. The goal is to establish clinical benefit of the immunotherapy (i.e., adjuvanted vaccine) over the standard of care. The adjuvant may have a low-level clinical effect that skews the trial, increasing the chances of a false negative.</li>\n<li>Base development decisions on clinical data rather than immune responses. Time-to-event end points are more valuable and clinically relevant.</li>\n<li>Design regulatory into the program from inception; invest in manufacturing and product assays early.</li></ul>\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Cancer_vaccine&amp;action=edit&amp;section=10\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a href=\"/wiki/Immunotherapy\" title=\"Immunotherapy\">Immunotherapy</a></li>\n<li><a href=\"/wiki/Cancer_immunotherapy\" title=\"Cancer immunotherapy\">Cancer immunotherapy</a>\n<ul><li><a href=\"/wiki/Coley%27s_toxins\" title=\"Coley&#39;s toxins\">Coley's toxins</a></li></ul></li>\n<li><a href=\"/wiki/HPV_vaccines#Therapeutic_vaccines\" class=\"mw-redirect\" title=\"HPV vaccines\">HPV vaccines#Therapeutic vaccines</a></li></ul>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Cancer_vaccine&amp;action=edit&amp;section=11\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist columns references-column-width\" style=\"-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;\">\n<ol class=\"references\">\n<li id=\"cite_note-1\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-1\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (2001-04-26). \"IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity\". <i>Nature</i>. <b>410</b> (6832): 1107\u20131111. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/35074122\">10.1038/35074122</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/11323675\">11323675</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature&amp;rft.atitle=IFNgamma+and+lymphocytes+prevent+primary+tumour+development+and+shape+tumour+immunogenicity.&amp;rft.volume=410&amp;rft.issue=6832&amp;rft.pages=1107-1111&amp;rft.date=2001-04-26&amp;rft_id=info%3Adoi%2F10.1038%2F35074122&amp;rft_id=info%3Apmid%2F11323675&amp;rft.aulast=Shankaran&amp;rft.aufirst=V&amp;rft.au=Ikeda%2C+H&amp;rft.au=Bruce%2C+AT&amp;rft.au=White%2C+JM&amp;rft.au=Swanson%2C+PE&amp;rft.au=Old%2C+LJ&amp;rft.au=Schreiber%2C+RD&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+vaccine\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-2\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-2\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Dunn GP, Old LJ, Schreiber RD (2004). \"The three Es of cancer immunoediting\". <i>Annu. Rev. Immunol</i>. <b>22</b> (i): 329\u201360. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1146/annurev.immunol.22.012703.104803\">10.1146/annurev.immunol.22.012703.104803</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/15032581\">15032581</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Annu.+Rev.+Immunol.&amp;rft.atitle=The+three+Es+of+cancer+immunoediting&amp;rft.volume=22&amp;rft.issue=i&amp;rft.pages=329-60&amp;rft.date=2004&amp;rft_id=info%3Adoi%2F10.1146%2Fannurev.immunol.22.012703.104803&amp;rft_id=info%3Apmid%2F15032581&amp;rft.aulast=Dunn&amp;rft.aufirst=GP&amp;rft.au=Old%2C+LJ&amp;rft.au=Schreiber%2C+RD&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+vaccine\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Babu2010-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Babu2010_3-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Arvind Babu RS; Kiran Kumar K; Sridhar Reddy G; Anuradha Ch (2010). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.jofs.in/temp/JOrofacSci2377-614488_170408.pdf\">\"Cancer Vaccine&#160;: A Review\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>Journal of Orofacial Sciences</i>. <b>2</b> (3): 77\u201382.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Orofacial+Sciences&amp;rft.atitle=Cancer+Vaccine+%3A+A+Review&amp;rft.volume=2&amp;rft.issue=3&amp;rft.pages=77-82&amp;rft.date=2010&amp;rft.au=Arvind+Babu+RS&amp;rft.au=Kiran+Kumar+K&amp;rft.au=Sridhar+Reddy+G&amp;rft.au=Anuradha+Ch&amp;rft_id=http%3A%2F%2Fwww.jofs.in%2Ftemp%2FJOrofacSci2377-614488_170408.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+vaccine\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><sup class=\"noprint Inline-Template\"><span style=\"white-space: nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Link_rot\" title=\"Wikipedia:Link rot\"><span title=\"&#160;Dead link since July 2017\">permanent dead link</span></a></i>&#93;</span></sup></span>\n</li>\n<li id=\"cite_note-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-4\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://vaccinenewsdaily.com/news/213394-oral-vaccine-could-fight-source-of-stomach-cancers\">\"Oral vaccine could fight source of stomach cancers\"</a>. Vaccine News Reports.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Oral+vaccine+could+fight+source+of+stomach+cancers&amp;rft.pub=Vaccine+News+Reports&amp;rft_id=http%3A%2F%2Fvaccinenewsdaily.com%2Fnews%2F213394-oral-vaccine-could-fight-source-of-stomach-cancers&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+vaccine\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-5\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Giarelli E (2007). \"Cancer vaccines: a new frontier in prevention and treatment\". <i>Oncology (Williston Park)</i>. <b>21</b> (11 Suppl Nurse Ed): 11\u20138. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/18154203\">18154203</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Oncology+%28Williston+Park%29&amp;rft.atitle=Cancer+vaccines%3A+a+new+frontier+in+prevention+and+treatment&amp;rft.volume=21&amp;rft.issue=11+Suppl+Nurse+Ed&amp;rft.pages=11-8&amp;rft.date=2007&amp;rft_id=info%3Apmid%2F18154203&amp;rft.au=Giarelli+E&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+vaccine\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:0-6\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:0_6-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:0_6-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\">Amgen press release. Amgen announces top-line results of phase 3 talimogene laherparepvec trial in melanoma. Mar 19, 2013. Available <a rel=\"nofollow\" class=\"external text\" href=\"http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1798143\">here</a></span>\n</li>\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=65&amp;abstractID=33572\">Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results.</a> S. J. Schuster, et al. 2009 ASCO Annual Meeting, J Clin Oncol 27:18s, 2009 (suppl; abstr 2)</span>\n</li>\n<li id=\"cite_note-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-8\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm210215.htm\">\"Approval Letter - Provenge\"</a>. <a href=\"/wiki/Food_and_Drug_Administration\" title=\"Food and Drug Administration\">Food and Drug Administration</a>. 2010-04-29.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Approval+Letter+-+Provenge&amp;rft.pub=Food+and+Drug+Administration&amp;rft.date=2010-04-29&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FBiologicsBloodVaccines%2FCellularGeneTherapyProducts%2FApprovedProducts%2Fucm210215.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+vaccine\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-9\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.genengnews.com/analysis-and-insight/what-comes-after-dendreon-s-provenge/77899342/\">\"What Comes After Dendreon's Provenge?\"</a>. 18 Oct 2010.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=What+Comes+After+Dendreon%27s+Provenge%3F&amp;rft.date=2010-10-18&amp;rft_id=http%3A%2F%2Fwww.genengnews.com%2Fanalysis-and-insight%2Fwhat-comes-after-dendreon-s-provenge%2F77899342%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+vaccine\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-10\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.the-scientist.com/templates/trackable/display/blog.jsp?type=blog&amp;id=54528&amp;o_url=blog/display/54528\">\"Dead\"</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Dead&amp;rft_id=http%3A%2F%2Fwww.the-scientist.com%2Ftemplates%2Ftrackable%2Fdisplay%2Fblog.jsp%3Ftype%3Dblog%26id%3D54528%26o_url%3Dblog%2Fdisplay%2F54528&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+vaccine\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><sup class=\"noprint Inline-Template\"><span style=\"white-space: nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Link_rot\" title=\"Wikipedia:Link rot\"><span title=\"&#160;Dead link since June 2016\">dead link</span></a></i>&#93;</span></sup></span>\n</li>\n<li id=\"cite_note-Pejawar-Gaddy_S_2008-11\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Pejawar-Gaddy_S_2008_11-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Pejawar-Gaddy_S_2008_11-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Pejawar-Gaddy S, Finn O (2008). \"Cancer vaccines: Accomplishments and challenges\". <i>Critical Reviews in Oncology Hematology</i>. <b>67</b>: 93\u2013102. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.critrevonc.2008.02.010\">10.1016/j.critrevonc.2008.02.010</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Critical+Reviews+in+Oncology+Hematology&amp;rft.atitle=Cancer+vaccines%3A+Accomplishments+and+challenges&amp;rft.volume=67&amp;rft.pages=93-102&amp;rft.date=2008&amp;rft_id=info%3Adoi%2F10.1016%2Fj.critrevonc.2008.02.010&amp;rft.aulast=Pejawar-Gaddy&amp;rft.aufirst=S&amp;rft.au=Finn%2C+O&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+vaccine\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-12\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Nishikawa, Makiya; Takemoto, Seiji; Takakura, Yoshinobu (2008-04-16). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.sciencedirect.com/science/article/pii/S0378517307008174\">\"Heat shock protein derivatives for delivery of antigens to antigen presenting cells\"</a>. <i>International Journal of Pharmaceutics</i>. Special Issue in Honor of Prof. Tsuneji Nagai. <b>354</b> (1\u20132): 23\u201327. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.ijpharm.2007.09.030\">10.1016/j.ijpharm.2007.09.030</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=International+Journal+of+Pharmaceutics&amp;rft.atitle=Heat+shock+protein+derivatives+for+delivery+of+antigens+to+antigen+presenting+cells&amp;rft.volume=354&amp;rft.issue=1%E2%80%932&amp;rft.pages=23-27&amp;rft.date=2008-04-16&amp;rft_id=info%3Adoi%2F10.1016%2Fj.ijpharm.2007.09.030&amp;rft.aulast=Nishikawa&amp;rft.aufirst=Makiya&amp;rft.au=Takemoto%2C+Seiji&amp;rft.au=Takakura%2C+Yoshinobu&amp;rft_id=http%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS0378517307008174&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+vaccine\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-13\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Savvateeva, L. V.; Schwartz, A. M.; Gorshkova, L. B.; Gorokhovets, N. V.; Makarov, V. A.; Reddy, V. P.; Aliev, G.; Zamyatnin, A. A. (2015-01-01). \"Prophylactic Admission of an In Vitro Reconstructed Complexes of Human Recombinant Heat Shock Proteins and Melanoma Antigenic Peptides Activates Anti-Melanoma Responses in Mice\". <i>Current Molecular Medicine</i>. <b>15</b> (5): 462\u2013468. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.2174/1566524015666150630125024\">10.2174/1566524015666150630125024</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/1875-5666\">1875-5666</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/26122656\">26122656</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Current+Molecular+Medicine&amp;rft.atitle=Prophylactic+Admission+of+an+In+Vitro+Reconstructed+Complexes+of+Human+Recombinant+Heat+Shock+Proteins+and+Melanoma+Antigenic+Peptides+Activates+Anti-Melanoma+Responses+in+Mice&amp;rft.volume=15&amp;rft.issue=5&amp;rft.pages=462-468&amp;rft.date=2015-01-01&amp;rft.issn=1875-5666&amp;rft_id=info%3Apmid%2F26122656&amp;rft_id=info%3Adoi%2F10.2174%2F1566524015666150630125024&amp;rft.aulast=Savvateeva&amp;rft.aufirst=L.+V.&amp;rft.au=Schwartz%2C+A.+M.&amp;rft.au=Gorshkova%2C+L.+B.&amp;rft.au=Gorokhovets%2C+N.+V.&amp;rft.au=Makarov%2C+V.+A.&amp;rft.au=Reddy%2C+V.+P.&amp;rft.au=Aliev%2C+G.&amp;rft.au=Zamyatnin%2C+A.+A.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+vaccine\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-14\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Rosenberg SA, Yang JC, Restifo NP (September 2004). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC1435696\">\"Cancer immunotherapy: moving beyond current vaccines\"</a>. <i>Nat. Med</i>. <b>10</b> (9): 909\u201315. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/nm1100\">10.1038/nm1100</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC1435696\">1435696</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/15340416\">15340416</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nat.+Med.&amp;rft.atitle=Cancer+immunotherapy%3A+moving+beyond+current+vaccines&amp;rft.volume=10&amp;rft.issue=9&amp;rft.pages=909-15&amp;rft.date=2004-09&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1435696&amp;rft_id=info%3Apmid%2F15340416&amp;rft_id=info%3Adoi%2F10.1038%2Fnm1100&amp;rft.aulast=Rosenberg&amp;rft.aufirst=SA&amp;rft.au=Yang%2C+JC&amp;rft.au=Restifo%2C+NP&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1435696&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+vaccine\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-15\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Johnson, Robert S.; Walker, Anthony I.; Ward, Stephen J. (2009-01-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://dx.doi.org/10.1586/14737140.9.1.67\">\"Cancer vaccines: will we ever learn?\"</a>. <i>Expert Review of Anticancer Therapy</i>. <b>9</b> (1): 67\u201374. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1586/14737140.9.1.67\">10.1586/14737140.9.1.67</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/1473-7140\">1473-7140</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Expert+Review+of+Anticancer+Therapy&amp;rft.atitle=Cancer+vaccines%3A+will+we+ever+learn%3F&amp;rft.volume=9&amp;rft.issue=1&amp;rft.pages=67-74&amp;rft.date=2009-01-01&amp;rft_id=info%3Adoi%2F10.1586%2F14737140.9.1.67&amp;rft.issn=1473-7140&amp;rft.aulast=Johnson&amp;rft.aufirst=Robert+S.&amp;rft.au=Walker%2C+Anthony+I.&amp;rft.au=Ward%2C+Stephen+J.&amp;rft_id=https%3A%2F%2Fdx.doi.org%2F10.1586%2F14737140.9.1.67&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+vaccine\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div>\n<h2><span class=\"mw-headline\" id=\"External_links\">External links</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Cancer_vaccine&amp;action=edit&amp;section=12\" title=\"Edit section: External links\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cancerresearch.org/scientists/clinical-development/cancer-immunotherapy-consortium\">Cancer Immunotherapy Consortium</a> (coordinated early-phase clinical trials of therapeutic cancer vaccines)</li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"https://www.sitcancer.org\">Society for Immunotherapy of Cancer</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.c-imt.org\">Association for the Immunotherapy of Cancer</a></li></ul>\n\n<!-- \nNewPP limit report\nParsed by mw2152\nCached time: 20180915170559\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.192 seconds\nReal time usage: 0.247 seconds\nPreprocessor visited node count: 930/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 27840/2097152 bytes\nTemplate argument size: 1165/2097152 bytes\nHighest expansion depth: 12/40\nExpensive parser function count: 2/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 18339/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.098/10.000 seconds\nLua memory usage: 4.12 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  204.680      1 -total\n 76.03%  155.624      1 Template:Reflist\n 38.98%   79.787      9 Template:Cite_journal\n 19.10%   39.097      1 Template:About\n 14.93%   30.568      2 Template:Dead_link\n 12.20%   24.962      2 Template:Fix\n 10.53%   21.548      4 Template:Category_handler\n  5.42%   11.092      3 Template:Cite_web\n  2.26%    4.625      1 Template:Cite_news\n  1.84%    3.766      2 Template:Fix/category\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:793631-0!canonical and timestamp 20180915170559 and revision id 859689143\n -->\n</div>"},"langlinks":[{"lang":"ar","url":"https://ar.wikipedia.org/wiki/%D9%84%D9%82%D8%A7%D8%AD_%D8%A7%D9%84%D8%B3%D8%B1%D8%B7%D8%A7%D9%86","langname":"Arabic","autonym":"\u0627\u0644\u0639\u0631\u0628\u064a\u0629","*":"\u0644\u0642\u0627\u062d \u0627\u0644\u0633\u0631\u0637\u0627\u0646"},{"lang":"bg","url":"https://bg.wikipedia.org/wiki/%D0%92%D0%B0%D0%BA%D1%81%D0%B8%D0%BD%D0%B0_%D0%BF%D1%80%D0%BE%D1%82%D0%B8%D0%B2_%D1%80%D0%B0%D0%BA","langname":"Bulgarian","autonym":"\u0431\u044a\u043b\u0433\u0430\u0440\u0441\u043a\u0438","*":"\u0412\u0430\u043a\u0441\u0438\u043d\u0430 \u043f\u0440\u043e\u0442\u0438\u0432 \u0440\u0430\u043a"},{"lang":"de","url":"https://de.wikipedia.org/wiki/Krebsimpfstoff","langname":"German","autonym":"Deutsch","*":"Krebsimpfstoff"},{"lang":"fr","url":"https://fr.wikipedia.org/wiki/Vaccin_contre_le_cancer","langname":"French","autonym":"fran\u00e7ais","*":"Vaccin contre le cancer"},{"lang":"ja","url":"https://ja.wikipedia.org/wiki/%E3%81%8C%E3%82%93%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3","langname":"Japanese","autonym":"\u65e5\u672c\u8a9e","*":"\u304c\u3093\u30ef\u30af\u30c1\u30f3"},{"lang":"ru","url":"https://ru.wikipedia.org/wiki/%D0%9F%D1%80%D0%BE%D1%82%D0%B8%D0%B2%D0%BE%D1%80%D0%B0%D0%BA%D0%BE%D0%B2%D0%B0%D1%8F_%D0%B2%D0%B0%D0%BA%D1%86%D0%B8%D0%BD%D0%B0","langname":"Russian","autonym":"\u0440\u0443\u0441\u0441\u043a\u0438\u0439","*":"\u041f\u0440\u043e\u0442\u0438\u0432\u043e\u0440\u0430\u043a\u043e\u0432\u0430\u044f \u0432\u0430\u043a\u0446\u0438\u043d\u0430"},{"lang":"fi","url":"https://fi.wikipedia.org/wiki/Sy%C3%B6p%C3%A4rokote","langname":"Finnish","autonym":"suomi","*":"Sy\u00f6p\u00e4rokote"},{"lang":"ur","url":"https://ur.wikipedia.org/wiki/%D8%A8%D9%82%D8%B1%DB%8C%D8%A7%D8%AA%D9%90_%D8%B9%D9%84%D9%85_%D8%A7%D9%84%D8%A7%D9%88%D8%B1%D8%A7%D9%85","langname":"Urdu","autonym":"\u0627\u0631\u062f\u0648","*":"\u0628\u0642\u0631\u06cc\u0627\u062a\u0650 \u0639\u0644\u0645 \u0627\u0644\u0627\u0648\u0631\u0627\u0645"},{"lang":"vi","url":"https://vi.wikipedia.org/wiki/V%E1%BA%AFc-xin_ung_th%C6%B0","langname":"Vietnamese","autonym":"Ti\u1ebfng Vi\u1ec7t","*":"V\u1eafc-xin ung th\u01b0"},{"lang":"zh","url":"https://zh.wikipedia.org/wiki/%E7%99%8C%E7%97%87%E7%96%AB%E8%8B%97","langname":"Chinese","autonym":"\u4e2d\u6587","*":"\u764c\u75c7\u75ab\u82d7"}],"categories":[{"sortkey":"","hidden":"","*":"All_articles_with_dead_external_links"},{"sortkey":"","hidden":"","*":"Articles_with_dead_external_links_from_July_2017"},{"sortkey":"","hidden":"","*":"Articles_with_permanently_dead_external_links"},{"sortkey":"","hidden":"","*":"Articles_with_dead_external_links_from_June_2016"},{"sortkey":"Cancer Vaccine","*":"Vaccination"},{"sortkey":" ","*":"Cancer_vaccines"}],"links":[{"ns":14,"exists":"","*":"Category:Articles with dead external links from July 2017"},{"ns":14,"exists":"","*":"Category:Articles with dead external links from June 2016"},{"ns":0,"exists":"","*":"Adaptive immune system"},{"ns":0,"exists":"","*":"Antigen"},{"ns":0,"exists":"","*":"Bacillus Calmette-Gu\u00e9rin"},{"ns":0,"exists":"","*":"BiovaxID"},{"ns":0,"exists":"","*":"Cancer"},{"ns":0,"exists":"","*":"CancerVax"},{"ns":0,"exists":"","*":"Cancer immunoprevention"},{"ns":0,"exists":"","*":"Cancer immunotherapy"},{"ns":0,"exists":"","*":"Cervical cancer"},{"ns":0,"exists":"","*":"Coley's toxins"},{"ns":0,"exists":"","*":"Cytokines"},{"ns":0,"exists":"","*":"Dendreon"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Epitope"},{"ns":0,"exists":"","*":"Follicular lymphoma"},{"ns":0,"exists":"","*":"Food and Drug Administration"},{"ns":0,"exists":"","*":"Food and Drug Administration (United States)"},{"ns":0,"exists":"","*":"GM-CSF"},{"ns":0,"exists":"","*":"HIV"},{"ns":0,"exists":"","*":"HPV vaccine"},{"ns":0,"exists":"","*":"HPV vaccines"},{"ns":0,"exists":"","*":"Helicobacter pylori"},{"ns":0,"exists":"","*":"Hepatitis B vaccine"},{"ns":0,"exists":"","*":"Hepatocellular carcinoma"},{"ns":0,"exists":"","*":"Herpes simplex virus"},{"ns":0,"exists":"","*":"Hormone-refractory prostate cancer"},{"ns":0,"exists":"","*":"Immune system"},{"ns":0,"exists":"","*":"Immunologic adjuvant"},{"ns":0,"exists":"","*":"Immunotherapy"},{"ns":0,"exists":"","*":"Influenza"},{"ns":0,"exists":"","*":"Innate immune system"},{"ns":0,"exists":"","*":"International Standard Serial Number"},{"ns":0,"exists":"","*":"Kidney cancer"},{"ns":0,"exists":"","*":"Melanoma"},{"ns":0,"exists":"","*":"Oncolytic viruses"},{"ns":0,"exists":"","*":"Oncophage"},{"ns":0,"exists":"","*":"Provenge"},{"ns":0,"exists":"","*":"PubMed Central"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"RECIST"},{"ns":0,"exists":"","*":"Renal cancer"},{"ns":0,"exists":"","*":"Sipuleucel-T"},{"ns":0,"exists":"","*":"Statistical power"},{"ns":0,"exists":"","*":"Talimogene laherparepvec"},{"ns":0,"exists":"","*":"Tumor antigen"},{"ns":0,"exists":"","*":"Types of cancer"},{"ns":0,"exists":"","*":"Vaccine"},{"ns":4,"exists":"","*":"Wikipedia:Link rot"}],"templates":[{"ns":10,"exists":"","*":"Template:About"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Column-width"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Dead link"},{"ns":10,"exists":"","*":"Template:Fix"},{"ns":10,"exists":"","*":"Template:Category handler"},{"ns":10,"exists":"","*":"Template:Fix/category"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:Cite news"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":828,"exists":"","*":"Module:About"},{"ns":828,"exists":"","*":"Module:Hatnote"},{"ns":828,"exists":"","*":"Module:Hatnote list"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Pagetype"},{"ns":828,"exists":"","*":"Module:Pagetype/config"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Namespace detect"},{"ns":828,"exists":"","*":"Module:Namespace detect/data"},{"ns":828,"exists":"","*":"Module:Namespace detect/config"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Unsubst"},{"ns":828,"exists":"","*":"Module:Category handler"},{"ns":828,"exists":"","*":"Module:Category handler/data"},{"ns":828,"exists":"","*":"Module:Category handler/config"},{"ns":828,"exists":"","*":"Module:Category handler/shared"},{"ns":828,"exists":"","*":"Module:Category handler/blacklist"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"}],"images":["Lock-green.svg"],"externallinks":["//doi.org/10.1038/35074122","//www.ncbi.nlm.nih.gov/pubmed/11323675","//doi.org/10.1146/annurev.immunol.22.012703.104803","//www.ncbi.nlm.nih.gov/pubmed/15032581","http://www.jofs.in/temp/JOrofacSci2377-614488_170408.pdf","http://vaccinenewsdaily.com/news/213394-oral-vaccine-could-fight-source-of-stomach-cancers","//www.ncbi.nlm.nih.gov/pubmed/18154203","http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1798143","http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33572","http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm210215.htm","http://www.genengnews.com/analysis-and-insight/what-comes-after-dendreon-s-provenge/77899342/","http://www.the-scientist.com/templates/trackable/display/blog.jsp?type=blog&id=54528&o_url=blog/display/54528","//doi.org/10.1016/j.critrevonc.2008.02.010","http://www.sciencedirect.com/science/article/pii/S0378517307008174","//doi.org/10.1016/j.ijpharm.2007.09.030","//doi.org/10.2174/1566524015666150630125024","//www.worldcat.org/issn/1875-5666","//www.ncbi.nlm.nih.gov/pubmed/26122656","//www.ncbi.nlm.nih.gov/pmc/articles/PMC1435696","//doi.org/10.1038/nm1100","//www.ncbi.nlm.nih.gov/pubmed/15340416","https://dx.doi.org/10.1586/14737140.9.1.67","//doi.org/10.1586/14737140.9.1.67","//www.worldcat.org/issn/1473-7140","https://www.cancerresearch.org/scientists/clinical-development/cancer-immunotherapy-consortium","https://www.sitcancer.org","http://www.c-imt.org"],"sections":[{"toclevel":1,"level":"2","line":"Traditional vaccines","number":"1","index":"1","fromtitle":"Cancer_vaccine","byteoffset":1138,"anchor":"Traditional_vaccines"},{"toclevel":1,"level":"2","line":"Method","number":"2","index":"2","fromtitle":"Cancer_vaccine","byteoffset":2364,"anchor":"Method"},{"toclevel":1,"level":"2","line":"Clinical trials","number":"3","index":"3","fromtitle":"Cancer_vaccine","byteoffset":3614,"anchor":"Clinical_trials"},{"toclevel":1,"level":"2","line":"Approved oncovaccines","number":"4","index":"4","fromtitle":"Cancer_vaccine","byteoffset":5913,"anchor":"Approved_oncovaccines"},{"toclevel":1,"level":"2","line":"Abandoned research","number":"5","index":"5","fromtitle":"Cancer_vaccine","byteoffset":6203,"anchor":"Abandoned_research"},{"toclevel":1,"level":"2","line":"Desirable characteristics","number":"6","index":"6","fromtitle":"Cancer_vaccine","byteoffset":6428,"anchor":"Desirable_characteristics"},{"toclevel":1,"level":"2","line":"Antigen candidates","number":"7","index":"7","fromtitle":"Cancer_vaccine","byteoffset":7364,"anchor":"Antigen_candidates"},{"toclevel":1,"level":"2","line":"Hypothesized problems","number":"8","index":"8","fromtitle":"Cancer_vaccine","byteoffset":9542,"anchor":"Hypothesized_problems"},{"toclevel":1,"level":"2","line":"Recommendations","number":"9","index":"9","fromtitle":"Cancer_vaccine","byteoffset":12996,"anchor":"Recommendations"},{"toclevel":1,"level":"2","line":"See also","number":"10","index":"10","fromtitle":"Cancer_vaccine","byteoffset":14142,"anchor":"See_also"},{"toclevel":1,"level":"2","line":"References","number":"11","index":"11","fromtitle":"Cancer_vaccine","byteoffset":14267,"anchor":"References"},{"toclevel":1,"level":"2","line":"External links","number":"12","index":"12","fromtitle":"Cancer_vaccine","byteoffset":14299,"anchor":"External_links"}],"parsewarnings":[],"displaytitle":"Cancer vaccine","iwlinks":[],"properties":[{"name":"defaultsort","*":"Cancer Vaccine"},{"name":"wikibase_item","*":"Q2378309"}]}}